

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization  
International Bureau



(43) International Publication Date  
5 April 2001 (05.04.2001)

PCT

(10) International Publication Number  
**WO 01/23016 A1**

- (51) International Patent Classification<sup>7</sup>: A61L 33/10, (74) Agent: VISSER-LUIRINK, Gesina; Octrooibureau LIOC, P.O. Box 13363, NL-3507 LJ Utrecht (NL).  
33/06, 27/34, 31/10
- (21) International Application Number: PCT/EP00/09658 (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW.
- (22) International Filing Date: 2 October 2000 (02.10.2000)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data: 99203203.7 30 September 1999 (30.09.1999) EP (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- (71) Applicant (*for all designated States except US*): ORBUS MEDICAL TECHNOLOGIES INC. [US/US]; 5363 NW 35th Avenue, Fort Lauderdale, FL 33309 (US).

(72) Inventors; and

(75) Inventors/Applicants (*for US only*): VAN DER GIESSEN, Wim [NL/NL]; Dr. Molenwaterplein 40, NL-3015 GD Rotterdam (NL). VAN BEUSEKOM, Heleen [NL/NL]; P.O. Box 1738, NL-3000 RD Rotterdam (NL).

**Published:**

— With international search report.

*For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.*

WO 01/23016 A1

(54) Title: INTRALUMINAL DEVICE, COATING FOR SUCH DEVICE, AND METHOD FOR PREPARING SAID DEVICE

(57) Abstract: Disclosed is an intraluminal device, suitable for implantation in a body. Said intraluminal device is provided with a coating which comprises: 50-97% heparan sulfate; 1-20% laminin; 0.2-15% type IV collagen. Furthermore a coating is disclosed, which coating is suitable for the above mentioned device, as well as a method for preparing such device, comprising the steps of: providing an intraluminal device for implantation in a body; preparing a composition, comprising, in about 50 mg/ml solvent: 50-97% heparan sulfate; 1-20% laminin; 0.2-15% type IV collagen; the solvent being a suitable buffer or water; dipping the intraluminal device in the composition; and drying the dipped intraluminal device.

Intraluminal device, coating for such device, and method for preparing said device

The present invention relates to an intraluminal device, suitable for implantation in a body, which intraluminal device is provided with a coating.

5

Intraluminal devices of the above mentioned type are generally known and applied. Such devices are for example applied in the treatment of blood vessel blockage in which the blocked blood vessel first is dilated, followed by placing a vascular prosthesis, in particular a stent, in the blood vessel in order to keep the vessel in the dilated state. This treatment does, however, give rise to several problems with regard to the vascular healing, as the natural healing process after such an operation is not regulated and as a consequence thereof undesirable local thrombosis can take place.

10

After the above implantation, the intraluminal device interacts with the vessel wall surface and the bloodstream. In a clinical setting the endothelialization of the intraluminal device is generally complete within two to three months after implantation. During this period the patient is at risk of thrombotic occlusion, undesired tissue growth, inflammation and vascular dysfunction.

15

There are several techniques available for controlling the above undesired effects of intraluminal devices, such as for example vascular stents. Thrombosis can passively be prevented by creating an inert surface which improves the surface characteristics that influence thrombosis. Such characteristics comprise, for example, charge, wettability and topography.

20

25

Thrombosis can also be prevented by binding one or more active components which inhibit thrombosis to the stent surface in order to actively prevent thrombosis. Examples of such components are prostaglandins, heparins, other thrombin inhibitors, or enzymes such as adenosine phosphatase.

30

Furthermore, thrombosis can be controlled by mimicking at the stent surface an already completed thrombotic response. This can be achieved by coating the stent surface with

fibrin, thereby creating a controlled thrombus in vitro, as polymerized and stabilised fibrin is no longer thrombogenic.

5 Thrombus formation can also be limited by disguising the stent surface with plasma proteins such as albumin, gamma globulins or phospholipids, which causes the skipping of certain phases in the proteinaceous - thrombotic and cellular - response.

The above mentioned coatings have an anti-proliferative effect; the growth velocity is inhibited in order to prevent thrombosis or restenosis.

10

A coating consisting of an extract of an extracellular biologically active basement membrane composition, derived for instance from the Engelbreth-Holm-Swarm tumor has been described in US patent 4,829,000. However, it appears that this membrane is not suitable as a stent coating because it forms a thick shell on the stent surface.

15

A. Schneider et al, J. Vasc. Surgery 15, 649 (1992) describe the application of a coating consisting of fibronectin whereupon bovine corneal endothelial cells grow. The cells were said to produce an extracellular matrix, and removed after 14 days. Thus coated polymer material was seeded with bovine aortic endothelial cells.

20

However, also this coating has a proliferative effect, viz. a large growth velocity of the cells but a big chance on thrombosis too. Moreover, this procedure is complicated and may suffer from bio-contamination.

25

The present invention aims to provide for an intraluminal device according to the preamble which after implantation in a body adds to an improvement of the process of vascular healing and which prevents the formation of thrombosis, excessive tissue growth, inflammation and vascular dysfunction.

In order to achieve this the present invention is directed to an intraluminal device according to the preamble, which is characterised in that the coating comprises:

30

50-97% heparan sulfate;

1-20% laminin;

0.2-15% type IV collagen.

By providing an intraluminal device with a coating of the above specified composition a suitable substrate is provided on which endothelial cells can adhere. During the growth  
5 the endothelial cells create their own matrix upon which to grow and remain attached. Given that the normal endothelium is non-thrombogenic, providing a coating suitable for endothelial cell growth can shorten the period during which a patient is at risk of thrombotic occlusion.

10 All of the above components are also naturally present in the basement membrane of the blood vessel wall and are suitable for endothelial cell adhesion, growth and differentiation. Laminin can contribute to the binding properties of the coating to, for example DNA and RNA in gene therapy. Furthermore, type IV collagen adds to an improved attachment of the coating on the intraluminal device as well as a better  
15 attachment of the endothelial cells on the coated surface of the intraluminal device. Finally, the heparan sulfate is an important component as it has an effective anti-thrombogenic effect.

The coating according to the present invention provides a surface which is higher up in  
20 the natural healing cycle. The coating provides a fertile rich environment for endothelial cells and regulated thrombus formation. Thus, contrary to the coatings according to the prior art, the coating according to the present invention has a proliferative effect. As a result of the proliferative effect, the vascular wound healing is stimulated thereby decreasing the period during which thrombosis can occur and excessive tissue growth.

25

In a particular embodiment the coating comprises:

75-95% heparan sulfate;

3-10% laminin;

0.5-10% type IV collagen.

30

In a further preferred embodiment the coating comprises entactin and nidogen.

Said compounds add to the structural integrity of the coating and also improve the attachment of the - endothelial - cells to the intraluminal device coating.

5 In another advantageous embodiment the coating furthermore comprises a growth factor.

Growth factors in general stimulate the growth of - for example, endothelial - cells and therefore enhance the proliferative effect.

10 Preferably, the growth factor is chosen from the group consisting of bFGF, IGF, TGF- $\beta$  and VEGF.

The different growth factors bFGF (basic fibroblast growth factor), IGF (insuline like growth factor), TGF- $\beta$  (transforming growth factor- $\beta$ ), and VEGF (vascular endothelial growth factor) all add to the growth of specific components.

15

In order to prevent any risk of infection, the coating advantageously comprises an antibiotic.

20 In order to have an optimal effect the antibiotic should be a broad spectrum antibiotic, such as gentamycine.

In a preferred embodiment the coating of the intraluminal device according to the present invention comprises vitronectin.

25

Vitronectin offers a good basis for cell attachment; moreover it binds abciximab, GP 2b/3b inhibitor (ReoPro<sup>®</sup>) which is a compound with a known anti-thrombotic effect. By incorporating vitronectin in the intraluminal device coating and administering to a patient ReoPro<sup>®</sup> or other drugs that bind to vitronectin, thrombosis is even further prevented.

30

-5-

In a particular preferred embodiment of the intraluminal device according to the present invention, the coating comprises:

- 85-95% heparan sulfate;
- 5-6% laminin;
- 5 3-4% type IV collagen;
- 0.5-1.5% entactin and nidogen;
- 0.001-1% growth factors;
- 0.001-1% antibiotic.

10 In a preferred embodiment the intraluminal device comprises a vascular prosthesis such as a stent or a graft. The stent as well as the graft can be prepared from different materials known to the person skilled in the art.

The coated intraluminal device according to the present invention can furthermore be  
15 used as a basis for therapies such as, for example, drug delivery and gene therapy. Drugs can be bound to the coating such that the release thereof is controlled. As mentioned in the above, the presence of laminin in the coating improves the bonds which are desired and required in gene therapy. It is also possible to provide for one or more radioactive molecules in the coating in order to inhibit cell growth, if desired.

20 The present invention also relates to a coating suitable for application to an intraluminal device according to the present invention.

It will be clear that such coating may also be used on other substrates which can be  
25 implanted in a body.

The present invention also relates to a method for preparing an intraluminal device according to the above invention, comprising the steps of:

- providing an intraluminal device such as a wire of stainless steel, tantalum or  
30 polytetrafluoroethylene (PTFE) for implantation in a body;
- preparing a composition, comprising, in about 50 mg/ml solvent:

50-97% heparan sulfate;

1-20% laminin;

0.2-15% type IV collagen;

the solvent being a suitable buffer or water;

- 5       - dipping the intraluminal device in the composition; and  
       - drying the dipped intraluminal device.

The method as such is very simple and easy to perform and moreover is not time-consuming. The drying step can take place with or without heated or forced air drying.

10

Preferred embodiments of the method according to the present invention are those wherein the compositions to be prepared furthermore comprise one or more of the group consisting of a growth factor such as bFGF, IGF, TGF- $\beta$  and VEGF, an antibiotic and vitronectin.

15

Preferably, a method for preparing a intraluminal device according to the above particular preferred embodiment, comprising the steps of:

- 20       - providing an intraluminal device such as a wire of stainless steel, tantalum or polytetrafluoroethylene (PTFE) for implantation in a body;  
       - preparing a composition, comprising, in about 50 mg/ml solvent:  
          85-95% heparan sulfate;  
          5-6% laminin;  
          3-4% type IV collagen;  
          0.5-1.5% entactin and nidogen;  
25       0.001-1% growth factors;  
          0.001-1% antibiotic;  
          the solvent being a suitable buffer or water;  
       - dipping the intraluminal device in the composition; and  
       - drying the dipped intraluminal device.

30

The present invention will be illustrated by the following, in no way the invention limiting, example.

#### Example

5

Helical coil, tantalum coronary stents were coated with the matrigel (n=2) as described in US patent 4,829,000 or with a coating according to the present invention (n=2).

10

The stents were percutaneously implanted using sterile techniques in coronary arteries of farm-bred Yorkshire swines (ca. 30 kg) in such a way that one of each stent was placed per animal.

15

One of the two matrigel coated stents showed thrombotic occlusion within one week. The stent coated according to the present invention in the same animal was in a good condition at autopsy. Mean neointimal thickness at one week was 24  $\mu\text{m}$  (range 20 - 44  $\mu\text{m}$ ) in the matrigel coated stent and 14  $\mu\text{m}$  (range 10 - 24  $\mu\text{m}$ ) in the stent coated according to the present invention.

20

In vitro platelet aggregation was measured in fresh, heparinized blood by measuring the impedance between the two electrodes. For this study the electrodes itself were coated with either matrigel or with the coating according to the present invention. Matrigel coating caused a decrease in impedance of 40 % compared to a bare electrode. The coating with a composition according to the present invention caused a decrease of 60 %. This implies a reduction of platelet aggregation in whole blood of the coating according to the present invention.



## Claims

1. Intraluminal device, suitable for implantation in a body, which device is provided with a coating, characterised in that the coating comprises:  
5 50-97% heparan sulfate;  
1-20% laminin;  
0.2-15% type IV collagen.
2. Intraluminal device according to claim 1, characterised in that the coating  
10 comprises:  
75-95% heparan sulfate;  
3-10% laminin;  
0.5-10% type IV collagen.
- 15 3. Intraluminal device according to claim 1 or 2, characterised in that the coating comprises entactin and nidogen.
4. Intraluminal device according to claim 1-3, characterised in that the coating furthermore comprises a growth factor.  
20
5. Intraluminal device according to claim 4, characterised in that the growth factor is chosen from the group consisting of bFGF, IGF, TGF- $\beta$  and VEGF.
6. Intraluminal device according one or more of the preceding claims, characterised  
25 in that the coating comprises an antibiotic.
7. Intraluminal device according to claim 6, characterised in that the antibiotic comprises gentamycine.
- 30 8. Intraluminal device according to one or more of the preceding claims, characterised in that the coating comprises vitronectine.

9. Intraluminal device according to one or more of the preceding claims, characterised in that the coating comprises:

- 85-95% heparan sulfate;
- 5-6% laminin,;
- 3-4% type IV collagen;
- 0.5-1.5% entactin and nidogen;
- 0.001-1% growth factors;
- 0.001-1% antibiotic.

10. Intraluminal device according to one or more of the preceding claims, characterised in that the prosthesis comprises a stent or a graft.

11. Coating suitable for a intraluminal device according to one or more of the preceding claims 1-10.

12. Method for preparing a intraluminal device according to one or more of the claims 1-10, comprising the steps of:

- providing a intraluminal device for implantation in a body;
- preparing a composition, comprising, in about 50 mg/ml solvent:
  - 50-97% heparan sulfate;
  - 1-20% laminin;
  - 0.2-15% type IV collagen;
  - the solvent being a suitable buffer or water;
- dipping the intraluminal device in the composition; and
- drying the dipped intraluminal device.

13. Method according to claim 12, characterised in that the composition comprises entactin and nidogen.

14. Method according to claim 12 or 13, characterised in that the composition furthermore comprises a growth factor, chosen from the group consisting of bFGF, IGF, TGF- $\beta$  and VEGF.

5 15. Method according to one or more of claims 12-14, characterised in that the composition comprises an antibiotic.

16. Method according to one or more of claims 12-15, characterised in that the composition comprises vitronectin.

10

17. Method according to one or more of the claims 12-16, characterised in that the composition comprises:

85-95% heparan sulfate;

5-6% laminin;

15 3-4% type IV collagen;

0.5-1.5% entactin and nidogen;

0.001-1% growth factors;

0.001-1% antibiotic.

## A. CLASSIFICATION OF SUBJECT MATTER

IPC 7 A61L33/10 A61L33/06 A61L27/34 A61L31/10

According to International Patent Classification (IPC) or to both national classification and IPC

## B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)

IPC 7 A61L

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

MEDLINE, EPO-Internal, WPI Data

## C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	SCHNEIDER A ET AL: "An improved method for endothelial cell seeding on polytetrafluoroethylene small caliber vascular grafts." JOURNAL OF VASCULAR SURGERY, (1992 APR) 15 (4) 649-56., XP000884442 the whole document	1,2
A	EP 0 945 145 A (SHIMIZU YASUHIKO ;TAPIC INTERNATIONAL CO LTD (JP)) 29 September 1999 (1999-09-29) claims; example 1	1-17
A	WO 95 31944 A (VEC TEC INC) 30 November 1995 (1995-11-30) claims; examples	1-17
-/--		

☒ Further documents are listed in the continuation of box C.☒ Patent family members are listed in annex.

## \* Special categories of cited documents:

\*A\* document defining the general state of the art which is not considered to be of particular relevance

\*E\* earlier document but published on or after the international filing date

\*L\* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)

\*O\* document referring to an oral disclosure, use, exhibition or other means

\*P\* document published prior to the international filing date but later than the priority date claimed

\*T\* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

\*X\* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

\*Y\* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.

\*Z\* document member of the same patent family

Date of the actual completion of the international search

14 December 2000

Date of mailing of the international search report

22/12/2000

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2  
NL - 2280 HV Rijswijk  
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl,  
Fax: (+31-70) 340-3016

Authorized officer

ESPINOSA, M

## C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO 99 01167 A (MINNESOTA MINING & MFG) 14 January 1999 (1999-01-14) page 3, line 1 - line 5 ---	1-17
A	US 4 963 146 A (LI SHU-TUNG) 16 October 1990 (1990-10-16) claims ---	1-17
A	DATABASE WPI Section Ch, Week 198630 Derwent Publications Ltd., London, GB; Class D16, AN 1986-194636 XP002131679 & JP 61 128974 A (ADV KAIHATSU KENKYU), 17 June 1986 (1986-06-17) abstract -----	1,2

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 0945145 A	29-09-1999	US 6090117 A	18-07-2000
		CN 1237914 A	08-12-1999
		WO 9822155 A	28-05-1998
WO 9531944 A	30-11-1995	US 5643712 A	01-07-1997
		AU 2517395 A	18-12-1995
		AU 2595195 A	18-12-1995
		EP 0759692 A	05-03-1997
		WO 9531897 A	30-11-1995
		US 5699793 A	23-12-1997
		US 6024698 A	15-02-2000
WO 9901167 A	14-01-1999	US 6146771 A	14-11-2000
		AU 5166298 A	25-01-1999
		EP 1021216 A	26-07-2000
US 4963146 A	16-10-1990	US 5026381 A	25-06-1991
JP 61128974 A	17-06-1986	NONE	